Hypera (HYPE3) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
14 Jul, 2026Executive summary
Net revenue reached R$2,227.2 million in 3Q25, up 16.3% year-over-year, driven by 8.3% retail sell-out growth and working capital optimization.
EBITDA margin from continuing operations expanded to 34.0% in 3Q25, compared to 29.3% in 3Q24, reflecting improved operating leverage and product mix.
Net income from continuing operations was R$453.9 million, with a net margin of 20.4%, up 22.6% year-over-year.
Operational cash flow hit a record R$853.6 million in the quarter, reflecting capital optimization and reduced working capital investments.
Interest on Equity of R$185.1 million (R$0.29/share) approved for the quarter.
Financial highlights
Gross profit for 3Q25 was R$1,362.0 million, up 18.9% year-over-year, with gross margin at 61.2%.
EBITDA from continuing operations grew 34.7% to R$756.2 million in 3Q25, margin at 34.0%.
Free cash flow in 3Q25 was R$688.8 million, a 24.8% increase year-over-year.
EPS for 3Q25 was R$0.72, up 21.6% year-over-year.
Net debt post-hedge ended the quarter at R$7,268.8 million, 2.4x annualized EBITDA.
Outlook and guidance
Focus on sustainable growth through innovation, new product launches, and market share expansion in key categories.
Continued investment in production capacity and digital media to support future growth.
Completed working capital optimization ahead of schedule, targeting R$2.5 billion in incremental operational cash generation by 2028.
No changes to previously disclosed projections; forward-looking statements depend on market, regulatory, and economic conditions.
Expect operational cash flow to be lower in Q4 due to dividend and OTCP payments.
Latest events from Hypera
- Net revenue up 86.7% YoY, EBITDA at R$586.5M, net debt down 17.8% after capital increase.HYPE3
Q1 202614 Jul 2026 - EBITDA margin held at 33.7% as working capital optimization improved cash metrics.HYPE3
Q2 202514 Jul 2026 - Net revenue fell 40.8%, but record cash flow and continued investments show resilience.HYPE3
Q1 202514 Jul 2026 - Sell-out up 11% and free cash flow up 23.2%, despite lower revenue and profit.HYPE3
Q3 202414 Jul 2026 - Sell-out up 6.3%, record cash flow, net debt down, and innovation pipeline drives outlook.HYPE3
Q2 202414 Jul 2026 - Net revenue fell 6% as working capital optimization drove record cash flow and strong sell-out.HYPE3
Q4 202414 Jul 2026 - Net revenue grew 3.4% to R$7.7B, with record cash flow and strong retail outperformance.HYPE3
Q4 20256 Jul 2026 - Market leader with strong growth, innovation, and broad branded portfolio in Brazilian pharma.HYPE3
Corporate presentation7 Apr 2026 - Working capital optimization and a 30 million share buyback aim for BRL 7.5 billion cash in 10 years.HYPE3
Status Update19 Jan 2026